Pharmacokinetics and Potential Interactions Amongst Antiretroviral Agents Used To Treat Patients with HIV Infection
暂无分享,去创建一个
David Back | Sara Gibbons | D. Back | C. Merry | F. Mulcahy | S. Gibbons | Fiona Mulcahy | Michael Barry | Concepta Merry | M. Barry
[1] S. Hammer,et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. , 1998, JAMA.
[2] D. Back,et al. Metabolism of Zidovudine. , 1995, General pharmacology.
[3] M A Fischl,et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. , 1987, The New England journal of medicine.
[4] D. Faulds,et al. Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. , 1996, Drugs.
[5] E. Acosta,et al. Clinical Pharmacokinetics of Zidovudine , 1996, Clinical pharmacokinetics.
[6] A. Breckenridge,et al. The pharmacokinetics of combination therapy with nelfinavir plus nevirapine , 1998, AIDS.
[7] M. Fischl,et al. Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection , 1997, Antimicrobial agents and chemotherapy.
[8] B. Clotet,et al. Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC , 1996, AIDS.
[9] N. Beeching,et al. Zidovudine pharmacokinetics in zidovudine-induced bone marrow toxicity. , 1994, British journal of clinical pharmacology.
[10] F. Wit,et al. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial , 1997 .
[11] D. Back,et al. Variability in trough plasma saquinavir concentrations in HIV patients--a case for therapeutic drug monitoring. , 1998, British journal of clinical pharmacology.
[12] L. Boone,et al. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity , 1997, Antimicrobial agents and chemotherapy.
[13] A. Breckenridge,et al. The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites , 1996, AIDS.
[14] G. Garber,et al. Pharmacokinetics of simultaneously administered zidovudine and didanosine in HIV-seropositive male patients. , 1995, Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology.
[15] J. Lipsky. Antiretroviral drugs for AIDS , 1996, The Lancet.
[16] N. Beeching,et al. Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome. , 1994, British journal of clinical pharmacology.
[17] D. Back,et al. Antiretroviral therapy for patients with HIV disease. , 1998, British journal of clinical pharmacology.
[18] S. Khoo,et al. Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro , 1997, Antimicrobial agents and chemotherapy.
[19] S. Khoo,et al. Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation. , 1996, AIDS.
[20] M. Niu,et al. Nevirapine, Zidovudine, and Didanosine Compared with Zidovudine and Didanosine in Patients with HIV-1 Infection , 1996, Annals of Internal Medicine.
[21] D. Back,et al. Effect of protease inhibitors on nucleoside analogue phosphorylation in vitro. , 1998, British journal of clinical pharmacology.
[22] K. Weinhold,et al. 3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase , 1987, Antimicrobial Agents and Chemotherapy.
[23] A. Pesce,et al. Pharmacokinetics of zidovudine phosphorylation in patients infected with the human immunodeficiency virus. , 1992, Therapeutic drug monitoring.
[24] J. Rockstroh,et al. Reply: Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. , 1997, AIDS.
[25] C. Flexner. HIV-protease inhibitors. , 1998, The New England journal of medicine.
[26] C. Perry,et al. Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. , 1997, Drugs.
[27] P M Gertman,et al. Iatrogenic illness on a general medical service at a university hospital* , 1981, Quality and Safety in Health Care.
[28] J. Darbyshire,et al. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals , 1996, The Lancet.
[29] D. Back,et al. Zalcitabine (ddC) Phosphorylation and Drug Interactions , 1995 .
[30] H. Ho,et al. Cellular pharmacology of 2',3'-dideoxy-2',3'-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus , 1989, Antimicrobial Agents and Chemotherapy.
[31] M. De Brabander,et al. Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients , 1996, AIDS.
[32] M. Dudley. Clinical pharmacokinetics of nucleoside antiretroviral agents. , 1995, The Journal of infectious diseases.
[33] S. Khoo,et al. Intracellular metabolism of zidovudine and stavudine in combination. , 1996, The Journal of infectious diseases.
[34] D. Back,et al. Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV‐infected patients , 1997, AIDS.
[35] ศิริลักษณ์ อนนันต์ณัฐศิริ,et al. Antiretroviral Therapy for HIV Infection in 1998 , 1998 .
[36] M. Barry,et al. Enzyme induction and inhibition. , 1990, Pharmacology & therapeutics.
[37] D. Greenblatt,et al. Protease Inhibitors as Inhibitors of Human Cytochromes P450: High Risk Associated with Ritonavir , 1998, Journal of clinical pharmacology.
[38] R. A. Torres,et al. Impact of combination therapy for HIV infection on inpatient census. , 1997, The New England journal of medicine.
[39] J. Montaner,et al. Drug Evaluations Anti-infectives: Nevirapine: A review of its development, pharmacological profile and potential for clinical use , 1996 .
[40] C. Debouck,et al. The HIV-1 protease as a therapeutic target for AIDS. , 1992, AIDS research and human retroviruses.
[41] Douglas D. Richman,et al. Antiretroviral therapy for HIV infection in 1996 : Recommendations of an international panel , 1996 .
[42] C. Perry,et al. Didanosine : An Update on its Antiviral Activity, Pharmacokinetic Properties and Therapeutic Efficacy in the Management of HIV Disease. , 1996, Drugs.
[43] S. Hammer,et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. , 1996, The New England journal of medicine.
[44] G. Satten,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.
[45] M. Feinberg. Changing the natural history of HIV disease , 1996, The Lancet.
[46] M A Fischl,et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. , 1997, The New England journal of medicine.
[47] G. Granneman,et al. Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions , 1997, Clinical pharmacokinetics.
[48] N. Cutler,et al. Pharmacokinetics of co-administered didanosine and stavudine in HIV-seropositive male patients. , 1994, British journal of clinical pharmacology.
[49] D. Back,et al. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. , 2003, British journal of clinical pharmacology.
[50] M. Hirsch,et al. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. , 1996, The Journal of infectious diseases.
[51] D. Back,et al. Effects of dideoxyinosine and dideoxycytidine on the intracellular phosphorylation of zidovudine in human mononuclear cells. , 1994, British journal of clinical pharmacology.
[52] D. Back,et al. Lamivudine (3TC) phosphorylation and drug interactions in vitro. , 1997, Biochemical pharmacology.
[54] P. Volberding,et al. Combination Therapy with Zidovudine and Didanosine Compared with Zidovudine Alone in HIV-1 Infection , 1993, Annals of Internal Medicine.
[55] S. Khoo,et al. In vitro screening of nucleoside analog combinations for potential use in anti-HIV therapy. , 1997, AIDS research and human retroviruses.
[56] R. Brettle,et al. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals , 1997, The Lancet.
[57] T. Steitz,et al. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[58] A. Breckenridge,et al. The effect of various drugs on the glucuronidation of zidovudine (azidothymidine; AZT) by human liver microsomes. , 1991, British journal of clinical pharmacology.
[59] D. Back,et al. Protease Inhibitors in Patients with HIV Disease , 1997, Clinical pharmacokinetics.